Trials / Completed
CompletedNCT00237120
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 15 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib |
Timeline
- Start date
- 2002-11-01
- Completion
- 2007-06-01
- First posted
- 2005-10-12
- Last updated
- 2009-11-23
Source: ClinicalTrials.gov record NCT00237120. Inclusion in this directory is not an endorsement.